News

OrbusNeich said that, in the investigator-initiated, single center, all-comers POTENT (Paclitaxel-eluting balloon and bio-engineered progenitor cell-attracting stainless steel stent in percutaneous treatment of coronary artery stenosis) registry, 32%

TraceLink and Catalent have designed the initial solution depending on the customers’ requirements for increased information and integration. Catalent is expected to work closely with customers to drive

Esperion Therapeutics is a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases. Under the terms of the agreement, TransGenRx is

Aztreonam for injection, USP is indicated for the treatment of infections caused by susceptible gram-negative microorganisms, including urinary tract infections, lower respiratory tract infections, septicemia, skin and skin-structure

Lipoxen said that the patent extends the PolyXen technology patent family in the US giving both Lipoxen and its license partners additional patent protection into 2025. Lipoxen stated

Comsol’s new module is built on the Comsol platform to create a single environment where engineers and scientists obtain accurate studies of material transport and chemical reactions of

Zydus Cadila said that the first molecule of the new class of anti-diabetic drugs called Glucagon Like Peptide-1 (GLP -1) agonists was approved by FDA in May 2005.

Gilead Sciences’ study showed that the patients receiving Cayston had a mean increase in FEV1 percent predicted from baseline to day 28 of 8.35% compared to 0.55% for

BioLineRx has received a total upfront payment of $30m with total clinical and regulatory milestones of up to $160m through to approval in the US, commercial milestones of